Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
04 January 2023 - 8:00AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that management will present
a company overview and participate in a Q&A session at the 41st
Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023
at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San
Francisco. This presentation will include an update on unaudited
fourth quarter and full year 2022 global net product revenues.
A live audio webcast of both the presentation and Q&A
session will be available on the Investors section of the Company’s
website, www.alnylam.com/events. A replay will be available on the
Alnylam website within 48 hours after the event.
About Alnylam Pharmaceuticals Alnylam Pharmaceuticals
(Nasdaq: ALNY) has led the translation of RNA interference (RNAi)
into a whole new class of innovative medicines with the potential
to transform the lives of people afflicted with rare and prevalent
diseases with unmet need. Based on Nobel Prize-winning science,
RNAi therapeutics represent a powerful, clinically validated
approach yielding transformative medicines. Since its founding 20
years ago, Alnylam has led the RNAi Revolution and continues to
deliver on a bold vision to turn scientific possibility into
reality. Alnylam’s commercial RNAi therapeutic products are
ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran),
AMVUTTRA® (vutrisiran) and Leqvio® (inclisiran), which is being
developed and commercialized by Alnylam’s partner, Novartis.
Alnylam has a deep pipeline of investigational medicines, including
multiple product candidates that are in late-stage development.
Alnylam is executing on its “Alnylam P5x25” strategy to deliver
transformative medicines in both rare and common diseases
benefiting patients around the world through sustainable innovation
and exceptional financial performance, resulting in a leading
biotech profile. Alnylam is headquartered in Cambridge, MA. For
more information about our people, science and pipeline, please
visit www.alnylam.com and engage with us on Twitter at @Alnylam, on
LinkedIn, or on Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230103005565/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media) 617-682-4340
Josh Brodsky (Investors) 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024